Co-Authors
This is a "connection" page, showing publications co-authored by ERIC A STROM and KAREN HOFFMAN.
Connection Strength
1.553
-
Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):441-448.
Score: 0.195
-
Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly? Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):49-51.
Score: 0.144
-
Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e283-90.
Score: 0.133
-
Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):116-122.
Score: 0.118
-
External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1464-72.
Score: 0.097
-
Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program. Breast. 2023 Apr; 68:205-215.
Score: 0.058
-
Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat. 2022 Aug; 195(1):33-41.
Score: 0.055
-
Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol. 2022 Mar-Apr; 7(2):100877.
Score: 0.053
-
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):426-436.
Score: 0.052
-
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):437-444.
Score: 0.052
-
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021 10 01; 111(2):360-370.
Score: 0.051
-
Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):574-581.
Score: 0.044
-
Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol. 2018 Oct 31; JCO1800317.
Score: 0.043
-
Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol. 2019 Jan; 9(1):e4-e13.
Score: 0.042
-
Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers (Basel). 2018 Apr 07; 10(4).
Score: 0.041
-
A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):252-257.
Score: 0.041
-
A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Ann Surg Oncol. 2017 Oct; 24(10):2965-2971.
Score: 0.039
-
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783.
Score: 0.039
-
Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct; 1(7):931-41.
Score: 0.035
-
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus. 2015; 4:36.
Score: 0.033
-
Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus. 2014; 3:166.
Score: 0.031
-
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
Score: 0.029
-
Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1089-94.
Score: 0.027
-
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
Score: 0.026
-
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 2011 Jul; 128(2):421-7.
Score: 0.025
-
Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):708-14.
Score: 0.025
-
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010 Sep 01; 116(17):4000-6.
Score: 0.024